See highlights from the Global Science Summit

Current Pipeline
miRNA

Encoded • ETX201

Encoded Therapeutics is exploring an investigational microRNA (miRNA) ETX201 knockdown approach to treating Angelman syndrome.

Discovery & DevPre-clinicalPhase 1Phase 2Phase 3To Patients

About the Program

This therapeutic approach utilizes specific pieces of RNA, called micro-RNA, that are delivered in an AAV virus to the brain, aimed to bind to the UBE3A-ATS and activate the silent paternal copy of the UBE3A gene in neurons.

Investigational Drug Name
ETX201
Company Website
Encoded Therapeutics

Program News

Encoded Therapeutics Presents Promising New Data for CNS Gene Therapy Programs at the ASGCT 28th Annual Meeting

Read More

An updated from Encoded Therapeutics on ETX201, a gene therapy clinical trial candidate for Angelman syndrome.

Read More

What are you looking for?

Find information on Angelman syndrome, research, clinical trials, resources, and ways to get involved.